计划状态
活跃，非招募阶段
第二阶段允许先接受免疫治疗
没有CRC 指导的试验
是药物
ALX148, cetuximab, Evorpacept (ALX148), Pembrolizumab, Erbitux, Keytruda标签
MSS/ MMRp评论
ALX148 + cetuximab + pembrolizumab for MSS patients who have received at least 2 lines of systemic therapy.
ALX148 (evorpacept): anti CD47, immunotherapy
Cetuximab: EGFR inhibitor (Erbitux)
Pembrolizumab: anti-PD1 checkpoint inhibitor, immunotherapy (Keytruda)
Left-sided RAS/BRAF Wild must have received EGFR inhibitor (cetuximab or panitumumab).
No prior checkpoint inhibitor (immunotherapy) allowed
| 地点 | 位置状态 |
|---|---|
| 美国 | |
|
University of Arizona Cancer Center Tucson, Arizona 85724 |
活跃，非招募 |
|
科罗拉多大学癌症中心 科罗拉多州奥罗拉 80045 |
活跃，非招募 |
|
Rutgers Cancer insititute 新泽西州新不伦瑞克 08903 |
活跃，非招募 |
|
Inova Schar Cancer Institute 弗吉尼亚州费尔法克斯 22031 |
活跃，非招募 |
纳入标准
纳入标准
To be eligible to participate in this study, an individual must meet all of the following criteria:
* Have a diagnosis of metastatic colorectal cancer previously treated with at least two lines of therapy for unresectable/metastatic disease
* Have microsatellite stable disease
* Adequate hematologic and end organ function
排除标准
排除标准：
An individual who meets any of the following criteria will be excluded from participation in this study:
* Patients with known MSI-high status or known mismatch repair deficiency (dMMR)
* Patients in whom both mismatch repair and microsatellite stability status are unknown
* History of severe allergic, anaphylactic, or other hypersensitivity reactions to any of the study medications or their classes
* Left-sided (at or distal to the splenic flexure) RAS/BRAF wild-type metastatic colorectal cancer who are EGFR inhibitor naïve.
* Prior therapy with an anti-PD-1, anti-PD-L1, anti PD L2, anti-CD47, or anti-SIRPα agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137)
